• Positive Phase 2b results for RAD 101 with 93% primary endpoint achievement
• Plans to initiate Phase 3 registrational trial of RAD 101 in Q4 2026
• Raised approximately $12.5M through an institutional offer
• Closing cash at the end of the quarter was $4.1 million

Radiopharm Theranostics announced significant progress in its clinical trials and financial activities for the quarter ended June 30, 2026. The company reported positive results from its Phase 2b clinical trial of RAD 101, an imaging agent for brain metastases, with 93% of evaluable patients achieving the primary endpoint. Based on these results, the company plans to initiate a Phase 3 registrational trial in Q4 2026. Additionally, Radiopharm Theranostics raised approximately $12.5M through an institutional offer and launched a $6 million Share Purchase Plan. The company's cash reserves decreased to $4.1 million at the end of the quarter, down from $19.2 million at the end of the prior quarter, primarily due to research and development expenditures and staff costs.

No specific financial guidance provided

The company expects to continue advancing its clinical programs and is optimistic about the potential of its pipeline of targeted radiopharmaceuticals.